key: cord-1001870-0ghzatib
authors: Kamarullah, William; Nurcahyani,; Mary Josephine, Claudia; Bill Multazam, Rachmatu; Ghaezany Nawing, Aqila
title: Corticosteroid Therapy in Management of Myocarditis Associated with COVID-19; a Systematic Review of Current Evidence
date: 2021-04-16
journal: Arch Acad Emerg Med
DOI: 10.22037/aaem.v9i1.1153
sha: c36fb090281c3ff991999baad3452b4a67e52532
doc_id: 1001870
cord_uid: 0ghzatib

INTRODUCTION: Myocarditis in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seems to be associated with a higher mortality rate. This study aims to summarize the latest evidence on whether the use of corticosteroids in patients with myocarditis associated with COVID-19 is necessary. METHODS: We performed an extensive search using a combination of search terms in PubMed, Europe PMC, ProQuest, EBSCOhost, and Google Scholar up to January 2021. Full-text articles that met the predefined inclusion criteria were included in the present study. RESULTS: The full-texts of 18 articles have been reviewed. Thirteen out of the eighteen (72%) patients who got corticosteroid administration experienced major clinical improvements during follow-up while the other five (28%) were experiencing uneventful events. The mean age of the reported patients was 47.8±13.2 years. There was no gender predominance. Most of the reported cases were from USA (39%) followed by Spain, China, and UK (11% each), while Brazil, Colombia, France, Belgium, and Italy contributed one case each. Various corticosteroids were used but the most commonly applied were methylprednisolone (89%), hydrocortisone (5.5%), and prednisolone (5.5%). The most common route of administration among the studies was intravenous administration and the duration of treatment varied between one and fourteen days. CONCLUSION: A review of the currently available literature shows that with the use of corticosteroid agents in treating myocarditis associated with COVID-19, favorable outcomes are attainable. Well-established randomized clinical trials are needed to evaluate the efficacy and safety of using corticosteroids in this condition.

Late in 2019, the world was staggered by the emergence of a new virus derived from Wuhan, China, which caused severe pneumonia and was later called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The diease caused by the virus was named coronavirus disease (1). This disease has led to more than 20 million active cases in 218 countries with more than 1.5 million people losing their lives (2) . In the midst of this pandemic, a lot is still yet to be discovered, including the true magnitude of the disease.

It was later discovered that since it binds with angiotensin converting enzyme (ACE) 2 receptors, which are also present in endothelial cells, it also affects the cardiovascular system and could manifest as myocarditis (3, 4) . As many studies investigating the mechanism of multiple organ dysfunction syndrome (MODS) associated with COVID-19 indicated, systemic hyper inflammation syndrome has become a leading theory to explain the condition (5) . Currently, there is no guideline that specifically addresses use of corticosteroids in treatment of myocarditis caused by COVID-19. Considering that uncertainty remains regarding this issue, we aimed to systematically review the use of corticosteroids in patients with myocarditis associated with COVID-19. We hypothesized that the addition of immunosuppressant therapy e.g. corticosteroids at this stage may reduce the severity of this hyperinflammatory condition. W. Kamarullah et al. 2 

This systematic review was conducted in line with the Cochrane Handbook for Systematic Reviews of Interventions and reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (6, 7) . The protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO), under registration number CRD42020223524.

Due to the lack of research articles, we performed a comprehensive search on case reports/series that presents patients with myocarditis associated with COVID-19 who were treated with corticosteroids using keywords ((COVID 19) OR (COVID-19) OR (Coronavirus) OR (Coronavirus disease) OR (Novel Coronavirus) OR (Novel human coronavirus) OR (SARS coronavirus) OR (SARS-CoV2) OR (SARS-CoV-2) OR (SARS CoV-2) OR (2019-nCoV)) AND ((Myocarditis) OR (Carditis) OR (Pericarditis) OR (Myopericarditis)) AND (Corticosteroid)) from the time in which SARS-CoV-2 was identified (January 2020) up until January 2021 through PubMed, EuropePMC, ProQuest, EBSCOhost, and Google Scholar. To ensure the identification of all relevant articles and publications, hand-searched articles from reference lists were also reviewed as an additional source of studies. We did not include words related to the outcomes of interest in order to obtain the largest number of search results possible. Our search was in line with PRISMA guidelines and the flowchart in Figure 1 portrays the search and screening processes.

In the present study, all cases using corticosteroids for patients with myocarditis associated with COVID-19 were included to be reviewed. Exclusion criteria comprised animal studies, expert opinions, literature review studies, news articles, letters, editorials, guidelines, and any studies that did not mention the outcomes and specify the corticosteroid used in the study. We also limited our search to articles written in English. The outcomes of interest were all-cause mortality, clinical improvement, and hospital discharge.

Articles were sorted based on whether titles or abstracts met the inclusion criteria. Full-text articles were then read, any duplicate studies were deleted, and those that did not satisfy the inclusion criteria were excluded. Data from the article were extracted and summarized using predesigned tables that consisted of name of the first author, year of publication, country in which the study was conducted, age and sex distribution of the patients, complete assessment of the patient, corticosteroid used, dose, route, and duration of administration, other medications, and outcomes. All steps of study selection and data collection process were conducted by all authors. Disagreements regarding study selection and data extraction were resolved through consensus-based discussion.

Two independent reviewers critically assessed the included studies using The Joanna Briggs Institute's critical assessment tool for case reports (8) . The presence of bias was determined for each article using the checklist of eight questions included in Table 2 . The articles received a score to indicate their degree of bias (low (included) and high (excluded)). For the purpose of this study, if "yes" was answered for more than half of the eight questions on the checklist, the study was considered to have a low risk of bias. Otherwise, answering "no" or "unclear" to half or more of the eight questions means the study was ascertained to have a high risk of bias and was excluded from this systematic review. Discrepancies in quality ratings were resolved through consensusbased discussion.

Five databases were used to find articles related to the use of corticosteroid in myocarditis associated with COVID-19. We found 3479 articles; out of which, eighteen case reports were then deemed eligible for inclusion in the present study (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . A PRISMA flow diagram detailing the process of identification, screening, inclusion, and exclusion of studies is shown in Figure 1 . The mean age of the reported patients was 47.8±13.2 years (range 18-69 years). There was no gender predominance. Most of the reported cases were from USA (39%) followed by Spain, China, and UK (11% each), while Brazil, Colombia, France, Belgium, and Italy contributed one case each. Various corticosteroids were used but the most commonly applied were methylprednisolone (89%), hydrocortisone (5.5%), and prednisolone (5.5%). The most common route of administration among the studies was intravenous administration and the duration of treatment varied between one and fourteen days. Other drugs were also used as combination therapy along with corticosteroids. Table 1 recounts the characteristics of the included studies.

All articles were determined to have low risk of bias. Seven other studies were identified as having high risk of bias and were excluded from the final inclusion process. Overall, studies did not report the adverse events resulting from the interventions. Moreover, low-level evidence from the included 3 Archives of Academic Emergency Medicine. 2021; 9(1): e32 studies could not explain the causal relationship between the interventions and the outcomes. A complete risk of bias assessment of the comprised studies is displayed in Table 2 .

Eighteen case reports administering corticosteroids to subjects with myocarditis associated with COVID-19 were included in this systematic review. These case reports described several types of corticosteroids, doses, routes of administration, and various outcomes. For instance, in the Colombian study conducted by Bernal-Torres et al. (9) , the authors described a 38-year-old woman without any comorbid conditions presenting with palpitations as well as general malaise since 3 days prior to admission. The patient had positive PCR examination on nasal swab for COVID-19. Furthermore, the patient was diagnosed with fulminant myocarditis associated with COVID-19 and was treated with intravenous immunosuppressant in the form of methylprednisolone. As a result, the patient experienced clinical improvement and was discharged on day 16. Case reports with similar population, without comorbid conditions, and with similar steroid therapy regimen were also provided by Garau et al. (12) , Hu et al. (13) , and Naneishvili et al. (19) . They showed progressive clinical improvements in various aspects. Higher dose of methylprednisolone was also found to provide good clinical improvements in studies performed by Salamanca et al. (22) and Sampaio et al. (23). Some patients with certain comorbidities such as hypertension (11, 18) , heart failure (15), and type 1 diabetes mellitus (21) showed clinical improvements as well. In addition, there were also various studies that did not specify the steroid dose used (14, 16) . Besides, it was not uncommon to use other types of corticosteroids such as hydrocortisone (11) as well as oral prednisolone (24), which provided good clinical improvements as well. Each and every study used other therapeutic agents, such as antibiotics (67%), hydroxychloroquine (50%), immunoglobulin (38%), antiviral drugs (27%), immunomodulators (27%), colchicine (22%), and other agents in addition to corticosteroid therapy to manage myocarditis associated with COVID-19 in patients. Regarding the outcomes, at the time of submission of those case reports, the majority of patients had survived (72%). Most of the patients who reportedly passed away were noted to have both acute respiratory distress syndrome (ARDS) and multiple-organ failure ( Table 1) . Most of the cases in this study were reported in sufficient detail; however, four reports did not specify the dose of the corticosteroid used and three of them did not report the duration of the corticosteroid's usage. The use of corticosteroids in myocarditis associated with COVID-19 seemed to have a better outcome in this small study. From the majority of those who got myocarditis from COVID-19 infection, good outcomes were reported more in those undergoing corticosteroid therapy (thirteen out of eighteen patients) compared with those who did not take a corticosteroid (five out of eighteen patients). The plausible explanation for these is that according to current researches, higher concentration of proinflammatory cytokines and chemokines were detected in patients with multiple organ dysfunction syndrome associated with COVID-19 due to exaggerated immune response to the virus (27). Based on this mechanism, corticosteroids can be clinically utilized to prevent the immune system from attracting more inflammatory cells to the tissue e.g. cardiac, which reduces inflammation (28). Recently, the European Society of Cardiology has issued a guidance in dealing with cardiovascular manifestations of COVID-19, yet there is no clear recommendation for the treatment of myocarditis associated with SARS-CoV-2 (29). Myocarditis is a potentially life-threatening disease. For this reason, from the current evidence that was drawn from this systematic review, the authors of this study proposed that corticosteroid must be considered as a last resort in terms of treating patients with myocarditis associated with COVID-19. This systematic review pooled case reports of patients with myocarditis caused by COVID-19 infection. Since this is a pooled case report, the evidence is weaker than controlled clinical trials. The number of cases was also small; there were only 18 cases from 18 studies. The findings of the pooled case reports might not apply to all patients, and the level of evidence is low. Secondly, the observed outcomes cannot be solely attributed to the corticosteroid therapy due to the combination of multiple drugs. This systematic review is a hypothesis-generating study. Further investigation needs to be done to obtain consecutive samples in a controlled study where the patients are blinded to corticosteroid therapy group and control group. However, the rarity of this event may impede such effort. In that case, the need for reviewing this matter in a systematic way was considered by the authors although good level of evidence were limitedly available.

The current systematic review showed that the use of corticosteroid agents is beneficial in improving the outcome of myocarditis associated with COVID-19. The present study showed that no randomized clinical trial has been performed with the aim of assessing the efficacy and safety of using corticosteroids for treating myocarditis associated with COVID-19, thus well-established randomized clinical trials should be pursued in order to confirm the findings of the present review.

W. Kamarullah et al. 4 

WK helped in the conception and design of the study. WK, N, CMJ, RBM, AGN, and SD were actively involved in literature search, study selection, data extraction, extensive review, and writing the manuscript. All authors read and approved the final submitted version.

None. 

Coronavirus disease (COVID-19) pandemic 2020

COVID-19 and multiorgan failure: A narrative review on potential mechanisms

COVID-19 and cardiovascular diseases

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Cochrane Handbook for Systematic Reviews of Interventions 2nd Edition

The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Case Reports

COVID-19 fulminant myocarditis: a case report

A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Sudden cardiogenic shock mimicking fulminant myocarditis in a surviving teenager affected by severe acute respiratory syndrome coronavirus 2 infection

Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin

COVID-19) Fulminant Myopericarditis and Acute Respiratory Distress Syndrome (ARDS) in a Middle-Aged Male Patient

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

COVID-19 (SARS-CoV-2) and the Heart -An Ominous Association

Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review

Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report

Fulminant myocarditis as an early presentation of SARS-CoV-2

Fulminant myocarditis due to COVID-19

An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection

The authors declared that no specific grant was received for this research from any funding agency in the public, commercial or not-for-profit sectors. There was no external funding to support this study and this study has no relationship with any industrial company.

The authors report no financial relationships or conflicts of interest regarding the content herein.

Archives of Academic Emergency Medicine. 2021; 9(1): e32